Comparable stake leader
Novo Holdings A/S
SEC ownership of Avalyn Pharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001540171.
Disclosed value leader
—
Comparable rows
0/15
Latest evidence
01 May 2026
- Symbol
- AVLN on Nasdaq
- SEC evidence covered
- 3/4/5
- Largest SEC-reported holder
- Novo Holdings A/S
- Latest parsed evidence date
- 01 May 2026
- CIK
- 0001540171
- Location
- Boston, MA
Ownership snapshot
1 signal
Issuer
2 identity fields
Ownership snapshot
Top shareholders of Avalyn Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
—
Comparable rows
0/15
Latest evidence
01 May 2026
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
15 rows are not safely comparable across share classes.
Showing 1-8 of 15 holder rows.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Detailed SEC evidence table Showing 1-8 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
3,883,289 shares
|
— | 01 May 2026 |
| FMR LLC |
3/4/5
Other*, 10%+ Owner
|
—
class O/S missing
|
—
2,284,535 shares
|
— | 01 May 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
1,275,486 shares
|
— | 01 May 2026 |
| Simeon George |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
1,122,087 shares
|
— | 01 May 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
1,122,087 shares
|
— | 01 May 2026 |
| Jill Carroll |
3/4/5
Director
|
—
class O/S missing
|
—
2,186,562 shares
|
— | 01 May 2026 |
| Lyn Baranowski |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
—
501,033 shares
|
— | 29 Apr 2026 |
| Adam H. Golden |
3/4/5
General Counsel
|
—
class O/S missing
|
—
254,891 shares
|
— | 29 Apr 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 02 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Avalyn Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Adam H. Golden
Net 12M change
$0
Latest report
01 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Adam H. Golden | General Counsel | Mixed | 29 Apr 2026 | |||
| Lyn Baranowski | Chief Executive Officer, Director | Mixed | 29 Apr 2026 | |||
| Douglas R. Carlson | Chief Financial Officer | Mixed | 29 Apr 2026 | |||
| Kate Haviland | Director | Mixed | 29 Apr 2026 | |||
| Howard Lazarus | Chief Medical Officer | Mixed | 29 Apr 2026 | |||
| Heather D. Turner | Director | Mixed | 29 Apr 2026 | |||
| Melissa Rhodes | Chief Operating Officer | Mixed | 29 Apr 2026 | |||
| David Matthew Friedman | Director | Mixed | 29 Apr 2026 | |||
| Jon Congleton | Director | Mixed | 29 Apr 2026 | |||
| Erin Lavelle | Director | Mixed | 29 Apr 2026 | |||
| Jill Carroll | Director | Mixed | 01 May 2026 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | Mixed | 01 May 2026 | |||
| Simeon George | 10%+ Owner | Mixed | 01 May 2026 | |||
| FMR LLC | Other*, 10%+ Owner | Mixed | 01 May 2026 | |||
| Novo Holdings A/S | 10%+ Owner | Mixed | 01 May 2026 | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | Mixed | 01 May 2026 |
Recent insider transactions for Avalyn Pharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | AVLN | Voting Common Stock | Purchase | 16.7% | 555,555 | 3,883,289 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Voting Common Stock | Conversion of derivative security | 3,327,734 | 3,327,734 | 01 May 2026 | Direct | |||
| Novo Holdings A/S | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -12,558,081 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -5,587,603 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -25,899,284 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -1,986,369 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -18,000,000 | 0 | 01 May 2026 | Direct | ||
| Fmr Llc | AVLN | Common Stock | Conversion of derivative security | 2,284,535 | 2,284,535 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | |||
| Fmr Llc | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -377,948 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -225,843 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -872,868 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -80,291 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -727,585 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Jill Carroll | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Jill Carroll | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Common Stock | Conversion of derivative security | 1,275,486 | 1,275,486 | 01 May 2026 | Direct | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -4,060,259 | 0 | 01 May 2026 | Direct | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -20,482,289 | 0 | 01 May 2026 | Direct | ||
| Douglas R. Carlson | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 30 Apr 2026 | Direct | |||
| Erin Lavelle | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 30 Apr 2026 | Direct | |||
| Adam H. Golden | AVLN | Stock Option (Right to Buy) | Award | 254,891 | 254,891 | 29 Apr 2026 | Direct | |||
| Jon Congleton | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Heather D. Turner | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Melissa Rhodes | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Kate Haviland | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Howard Lazarus | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Lyn Baranowski | AVLN | Stock Option (Right to Buy) | Award | 501,033 | 501,033 | 29 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.